{
  "docId": "019dd923-622c-750b-8b98-0c85e40ec39b",
  "docSlug": "9b248b07037e",
  "documentTitle": "CareDx, Inc. (CDNA)",
  "authorId": "53_Kerrisdale_Capital",
  "authorName": "Kerrisdale Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2019-07-01 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 6,
  "pageCount": 29,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "appendix_data",
  "function": "expose_gap",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses the NKF guidelines to argue that AlloSure's market is smaller than claimed by CareDx.",
  "elementsJson": [
    "paragraph",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b98-0c85e40ec39b/6",
  "deckHref": "/decks/019dd923-622c-750b-8b98-0c85e40ec39b",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b98-0c85e40ec39b.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b98-0c85e40ec39b#slide-6",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Poor clinical results leave CareDx open to significant regulatory and competitive risks.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-203e-77ad-a69c-7868fff42947",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.76,
        "x": 0.12,
        "y": 0.61
      },
      "kind": "paragraph",
      "text": "Poor clinical results leave CareDx open to significant regulatory and competitive risks. In addition to massive patient attrition, CareDx faces the risk of Medicare scaling back coverage.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b60dba7-c60c-45ae-bbb5-5ee1267f4a59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.76,
        "x": 0.12,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "The disclosures also suggest that over 90% of AlloSure revenue comes from these surveillance patients. Ironically, AlloSure's revenue comes almost entirely from transplant clinics studying it as a routine screening tool, but finding it so inadequate that they rapidly drop it.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f3794e8-57d4-4e4c-aab7-d1efb040e816",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.15,
        "y": 0.57
      },
      "kind": "source-note",
      "text": "Source: National Kidney Foundation: Managing Kidney Transplant Recipients",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ab92468-8db9-48e3-820a-53a90fe31375",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.7,
        "x": 0.15,
        "y": 0.23
      },
      "kind": "table",
      "text": "Routine screening intervals for various tests including Creatinine, Urine protein, CBC, Diabetes, Lipid profile, Tobacco use, BKV NAT, EBV NAT, and vitals.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a48b901-d8dc-4500-9527-d7097e899239",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.7,
        "x": 0.15,
        "y": 0.205
      },
      "kind": "title",
      "text": "National Kidney Foundation Routine Screening Guidelines for Clinicians",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6970cd10-1553-4566-8c69-c03f1c95075b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "03cd947c-8027-4c49-adc5-7d902b4a2252",
      "evidence": "Uses clinical guidelines to refute company market sizing claims.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 26,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6ece1bb9-6dc2-4b36-a983-1e6b3a2a754d",
      "evidence": "The document emphasizes the risks of not acting on AlloSure's ineffectiveness",
      "position": 0,
      "objective": "Highlight the cost of inaction for investors",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}